Toggle navigation
About Us
Who We Are
Management Team
Founders
Board of Directors
Core Values
Our Approach
& Programs
Gene Therapy
Pipeline
TRACER
TM
Our Programs
Manufacturing
Publications & Presentations
Patients
& Caregivers
Patient Resources
Expanded Access Policy
For Investors
& Media
Investor Overview
Stock information
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Annual Reports
Analyst Coverage
Investor FAQs
Contact
Join
Our Team
Who We Are
Benefits
Join Us
Contact
Toggle navigation
About Us
Who We Are
Management Team
Founders
Board of Directors
Core Values
Our Approach
& Programs
Gene Therapy
Pipeline
TRACER
TM
Our Programs
Manufacturing
Publications & Presentations
Patients
& Caregivers
Patient Resources
Expanded Access Policy
For Investors
& Media
Investor Overview
Stock information
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Annual Reports
Analyst Coverage
Investor FAQs
Contact
Join
Our Team
Who We Are
Benefits
Join Us
Contact
INTRAPUTAMINAL AADC GENE THERAPY (VY-AADC01) FOR ADVANCED PARKINSON’S DISEASE: INTERIM RESULTS OF A PHASE 1B TRIAL
